Floatz logo

Irinotecan

HER-2 Protein Overexpression

Jin-Hee AhnSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the HER-2 Protein Overexpression cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
NKGen Biotech, Inc.
Phase 2BB
Zanidatamab
Jazz Pharmaceuticals
Phase 2B
Pyrotinib
Tianjin Medical University Second Hospital
Phase 2CCC
her2 dc1 vaccine
H. Lee Moffitt Cancer Center and Research Institute
Phase 2CCC
Cetuximab
NKGen Biotech, Inc.
Phase 1/2CCC

View all 18 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →